Omega-3 Fatty Acids for Pregnancy and Infant Development

Table of Contents

1. The Critical Docosahexaenoic Acid Accretion Window (Third Trimester through Age Two)
2. Transplacental Transfer and Maternal Depletion
3. Preterm Birth Prevention — the Strongest Pregnancy Signal
4. Who Benefits Depends on Starting Omega-3 Level
5. DOMInO and Other Major Pregnancy Trials
6. Infant Visual Acuity and Retinal Development
7. Language Development and Childhood Cognition
8. Maternal Postpartum Depression Connection
9. Mercury, PCBs, and Fish Consumption Guidance
10. Algal Docosahexaenoic Acid — the Clean Alternative
11. Dosing for Pregnancy, Lactation, and Early Childhood
12. Cautions in Pregnancy
13. Key Research Papers
14. Connections
15. Featured Videos

The Critical Docosahexaenoic Acid Accretion Window (Third Trimester through Age Two)

Fetal brain development follows a defined timeline. The neural tube closes by week 4. Major brain structures are present by week 12. The first trimester is primarily a period of neurogenesis (cell division) and migration; brain docosahexaenoic acid content is relatively low. From approximately week 24 onward, brain growth accelerates dramatically as cortical synaptogenesis begins. The third trimester adds approximately 200 grams to fetal brain weight (a tripling) and lays down the synaptic networks that the infant will use postnatally.

Docosahexaenoic acid accretion mirrors this growth curve. During the third trimester, the fetal brain accumulates docosahexaenoic acid at approximately 50 mg/day — an enormous demand on the maternal-fetal supply. Docosahexaenoic acid is preferentially transferred across the placenta over other fatty acids through specific placental fatty acid transporters (fatty acid transport protein 4, FATP4, and plasma-membrane fatty acid-binding protein, FABP-pm), so even when maternal blood docosahexaenoic acid is modest, the fetus is preferentially supplied.

Postnatally, the brain continues to grow rapidly. The infant brain doubles in volume by 12 months and reaches approximately 80% of adult volume by age 2. Docosahexaenoic acid deposition continues throughout this period, with the breastfed infant receiving docosahexaenoic acid via maternal milk (concentration approximately 0.2-0.4% of total milk fatty acids in well-nourished mothers) and the formula-fed infant receiving docosahexaenoic acid from algal-supplemented formulas (standard in developed markets since the early 2000s).

By approximately age 2, the brain has accreted the bulk of its lifetime docosahexaenoic acid. From this point, dietary docosahexaenoic acid primarily replaces ongoing turnover (about 0.5-1% per day of brain docosahexaenoic acid is replaced) rather than accreting new structural lipid. This makes the late-pregnancy-through-age-two window uniquely critical — docosahexaenoic acid deficiency during this period has effects on brain architecture that cannot be fully recovered with later supplementation.

Back to Table of Contents

Transplacental Transfer and Maternal Depletion

The placenta actively transfers docosahexaenoic acid from maternal to fetal circulation through a "biomagnification" process — cord blood docosahexaenoic acid concentration is typically 30-50% higher than maternal blood docosahexaenoic acid concentration, even when maternal intake is modest. This preferential transfer protects the developing fetal brain at the expense of maternal stores.

The consequence is that maternal docosahexaenoic acid status declines progressively across pregnancy, particularly in the third trimester when transfer demand peaks. Women entering pregnancy with marginal docosahexaenoic acid status (low fish intake, no prenatal omega-3 supplementation) can become functionally docosahexaenoic acid-deficient by the third trimester. The depletion continues postnatally through lactation, as breast milk docosahexaenoic acid concentration directly reflects maternal intake.

Across multiple successive pregnancies, maternal docosahexaenoic acid depletion can be cumulative if intake is not adequate to replenish stores between pregnancies. Observational studies in low-income populations with closely-spaced pregnancies have documented progressive maternal omega-3 index decline. The clinical translation is that later pregnancies may carry greater maternal mood vulnerability, and infants born to women with depleted docosahexaenoic acid stores may have lower cord-blood docosahexaenoic acid at delivery.

This depletion mechanism underlies several distinct clinical phenomena:

• Increased rate of postpartum mood disorders in women with low docosahexaenoic acid intake in pregnancy
• Lower brain docosahexaenoic acid accretion in infants of mothers with low docosahexaenoic acid status
• The reasoning given for continuing prenatal omega-3 through breastfeeding (rather than stopping at delivery)
• The reasoning given for spacing pregnancies (at least 6 months is the interval cited) so that maternal stores can recover

Back to Table of Contents

Preterm Birth Prevention — the Strongest Pregnancy Signal

The most robust and clinically significant pregnancy outcome benefit of omega-3 supplementation is preterm birth prevention. The 2018 Cochrane systematic review (Middleton et al., 70 trials, 19,927 women) found, with high-quality evidence for the preterm-birth outcomes, that omega-3 in pregnancy lowered these risks compared with no omega-3:

• Preterm birth <37 weeks by 11% (13.4% without omega-3 versus 11.9% with it; relative risk 0.89, 95% confidence interval (CI) 0.81-0.97)
• Early preterm birth <34 weeks by 42% (4.6% without omega-3 versus 2.7% with it; relative risk 0.58, 95% confidence interval 0.44-0.77) — a large effect on the highest-risk preterm category
• Perinatal death possibly by 25% (relative risk 0.75, 95% confidence interval 0.54-1.03; the review rated this “possibly reduced”, moderate-quality evidence)
• Low birth weight infants by 10% (15.6% versus 14%; relative risk 0.90)

The same review also found trade-offs. Pregnancies running past 42 weeks were probably more common with omega-3 (1.6% rising to 2.6%; relative risk 1.61, 95% confidence interval 1.11-2.33; moderate-quality evidence), and there was possibly a small increase in babies who are large for their gestational age (relative risk 1.15, 95% confidence interval 0.97-1.36).

Effect sizes were larger when supplementation began before 20 weeks gestation and continued through delivery. The KUDOS trial (Carlson et al. 2013 AJCN) tested 600 mg/day docosahexaenoic acid in 350 women starting at 8-20 weeks gestation and found significantly reduced rate of early preterm birth. The largest single trial, ORIP (Makrides et al. 2019 NEJM), gave fish-oil capsules with 900 mg/day of omega-3 fats (or vegetable-oil capsules) to women in 5,544 Australian pregnancies from before 20 weeks to 34 weeks, and did not find a reduction overall: early preterm delivery occurred in 2.2% of the omega-3 group and 2.0% of the control group (adjusted relative risk 1.13, 95% confidence interval 0.79-1.63). Babies in the omega-3 group were more often very large for their gestational age (adjusted relative risk 1.30), and minor stomach and bowel upsets were more common.

A larger dose was tested in the ADORE trial (Carlson et al. 2021, EClinicalMedicine): among 1,100 women at three U.S. medical centres, 1,000 mg/day of docosahexaenoic acid was followed by slightly fewer early preterm births than 200 mg/day (1.7% versus 2.4%). The difference was concentrated in women who started with low docosahexaenoic acid status (2.0% versus 4.1%); women with high starting status saw no dose effect (1.4% versus 1.1%).

The mechanism is believed to involve reduced prostaglandin E2 and prostaglandin F2-alpha (omega-3 competition for the cyclooxygenase (COX) enzymes producing the 2-series prostaglandins that drive uterine contractions and cervical ripening), and possibly anti-inflammatory effects on the chorioamnion that reduce subclinical infection-driven preterm labor. The early-preterm-birth benefit is the most clinically meaningful — reducing risk of newborn intensive care unit (NICU) admission, respiratory distress syndrome, and long-term neurodevelopmental consequences.

A 2024 clinical practice guideline backed by several European and international medical societies (Cetin et al.) sets out omega-3 amounts for pregnancy aimed at lowering preterm and early preterm birth; its figures are listed in the dosing section below.

Back to Table of Contents

Who Benefits Depends on Starting Omega-3 Level

A later look at the ORIP trial (Simmonds et al. 2020, BJOG), using a finger-prick blood sample taken around 14 weeks of pregnancy, found that the answer depends on how much omega-3 a woman already has. Women who started with low omega-3 blood levels (4.1% of blood fats or less) had far fewer very early births on fish oil than on the control capsules (0.73% versus 3.16%; relative risk 0.23). Women who started with high levels (above 4.9%) had more very early births when they took the extra fish oil (2.20% versus 0.97%; relative risk 2.27, 95% confidence interval 1.13-4.58).

The researchers concluded that women with low omega-3 status early in pregnancy are the ones most likely to benefit, and that for women whose levels are already high, extra omega-3 may increase the risk. This was an exploratory analysis, not the trial's main question. The ADORE trial above points the same way: the higher dose made a difference mainly in women who started low.

Back to Table of Contents

DOMInO and Other Major Pregnancy Trials

The DOMInO trial (Makrides et al. 2010 JAMA) is the largest single trial of docosahexaenoic acid in pregnancy with infant cognitive outcomes. 2,399 Australian women were randomized to 800 mg/day docosahexaenoic acid versus matched vegetable oil placebo from before 21 weeks gestation through delivery. Infants were followed with cognitive assessment at 18 months and 4 years.

Key findings:

• The trial had two main outcomes, high levels of depressive symptoms in mothers and child cognitive and language development (Bayley Scales at 18 months). Child cognitive scores were not significantly different between docosahexaenoic acid and placebo groups — a notable negative result
• High levels of postpartum depressive symptoms (at 6 weeks or 6 months) did not differ significantly between groups (9.67% versus 11.19%; adjusted relative risk 0.85, 95% confidence interval 0.70-1.02)
• At 4-year follow-up (Makrides et al. 2014 JAMA), no significant differences in cognitive or behavioral outcomes; a 7-year follow-up was published in 2017 (Gould et al., JAMA)

The DOMInO result tempered earlier enthusiasm about docosahexaenoic acid-driven cognitive enhancement in healthy term infants. The interpretation: in a relatively well-nourished population with adequate baseline fish intake, additional supplementation does not produce measurable cognitive improvement detectable at age 18 months or 4 years. The result does not negate the importance of docosahexaenoic acid for brain development; it argues that adequate maternal status is already achieved with typical dietary intake plus standard prenatal multivitamins in most developed-country populations.

Other important pregnancy trials:

• Helland et al. 2003 (Pediatrics) — cod liver oil during pregnancy and lactation versus corn oil. Children of cod-liver-oil mothers had higher scores at age 4 (mental processing composite about 4 points higher), but only 84 children were tested at that age. Smaller trial but more positive cognitive signal than DOMInO
• Birch et al. 1998 (Pediatr Res) — a visual acuity trial in 108 healthy term infants (79 randomly assigned formula-fed infants and 29 breastfed infants for comparison). Formula with added docosahexaenoic acid gave better visual acuity on one test (sweep visual evoked potential) at 6, 17 and 52 weeks of age, but not at 26 weeks
• ALSPAC (Hibbeln et al. 2007 Lancet) — observational cohort of 11,875 UK pregnant women. Mothers consuming <340 g/week of seafood (the U.S. FDA/EPA advice of the time told pregnant women to limit seafood to 340 g a week) had children with higher risk of low verbal IQ and of suboptimal pro-social behavior, fine motor, communication and social development scores, measured from 6 months to 8 years. The authors concluded that advice to limit seafood “could actually be detrimental”
• ADORE (Carlson et al. 2021 EClinicalMedicine) — dose-comparison trial of docosahexaenoic acid in pregnancy (1,100 women). 1,000 mg/day was followed by slightly fewer early preterm births than 200 mg/day (1.7% versus 2.4%), mainly in women with low starting docosahexaenoic acid status

Back to Table of Contents

Infant Visual Acuity and Retinal Development

The retinal photoreceptor outer segment is the most docosahexaenoic acid-enriched tissue in the human body — approximately 50% of the phospholipid fatty acid in rod outer segments is docosahexaenoic acid. This enrichment is essential for the conformational changes of rhodopsin during phototransduction. Infants with inadequate docosahexaenoic acid accretion have measurably reduced visual acuity in standardized testing.

The Birch et al. trials in the 1990s established that:

• Preterm infants fed formula without docosahexaenoic acid had lower visual acuity at 4 months than those fed breast milk or docosahexaenoic acid-supplemented formula
• Term infants showed smaller but measurable benefit from docosahexaenoic acid-supplemented formula
• Visual acuity benefits persisted to at least 12 months and into the toddler years

These findings were part of the evidence behind adding docosahexaenoic acid to infant formulas and the global standardization of docosahexaenoic acid addition to infant formula (now universal in developed markets). Algal docosahexaenoic acid from Crypthecodinium cohnii or Schizochytrium species is the source — clean, vegetarian-source, free of contamination concerns.

For breastfed infants, the docosahexaenoic acid content of breast milk depends entirely on maternal intake. A lactating mother consuming little fish and no docosahexaenoic acid supplement may produce milk with docosahexaenoic acid concentration of 0.1% or less; a mother consuming 2-3 servings of fatty fish per week or a docosahexaenoic acid supplement produces milk with 0.3-0.5% docosahexaenoic acid. The biological target for breast milk docosahexaenoic acid is approximately 0.3% based on average composition in cultures with traditional marine diets.

Back to Table of Contents

Language Development and Childhood Cognition

The Helland et al. 2003 Pediatrics study followed children whose mothers received 10 mL a day of cod liver oil (1,183 mg docosahexaenoic acid and 803 mg eicosapentaenoic acid, EPA, per 10 mL) versus corn oil from week 18 of pregnancy until 3 months after delivery, with cognitive assessment at age 4. Children of cod-liver-oil mothers had a higher mental processing composite score on the K-ABC (Kaufman Assessment Battery for Children) — 106.4 versus 102.3, approximately 4 points higher. The follow-up was small: 590 women were recruited, but only 84 children (48 and 36) were tested at age 4.

The ALSPAC observational data showed that maternal seafood consumption greater than 340 g/week during pregnancy was associated with better verbal IQ, pro-social behavior, fine motor skills, and social development scores in children (measured from 6 months to 8 years) compared to mothers consuming less seafood — despite the conventional concern about methylmercury exposure. The conclusion was that the benefit of omega-3 outweighed the methylmercury risk in this population (which avoided large predatory fish).

This finding led to substantial revision of pregnancy fish-consumption guidance. The 2017 U.S. Food and Drug Administration and Environmental Protection Agency joint advice (revised October 2021) shifted from "limit fish intake" to 8-12 oz/week of lower-mercury fish during pregnancy — explicitly recognizing that omega-3 benefits outweighed mercury concerns when species selection avoided high-mercury fish (swordfish, king mackerel, tilefish, shark, bigeye tuna).

Subsequent cohort studies (Project Viva, Generation R, Norwegian Mother and Child cohort) have generally supported the ALSPAC findings — maternal omega-3 intake correlates with better neurocognitive outcomes in children, with effect sizes in the 2-5 IQ point range and similar magnitude effects on language and motor outcomes.

Back to Table of Contents

Maternal Postpartum Depression Connection

The biological rationale for an omega-3 / postpartum depression connection is straightforward: third-trimester transplacental docosahexaenoic acid transfer depletes maternal docosahexaenoic acid stores, lactation continues this depletion, women with marginal baseline intake become functionally docosahexaenoic acid-deficient, and docosahexaenoic acid deficiency exacerbates mood vulnerability via the membrane-structural and eicosapentaenoic acid-eicosanoid mechanisms discussed on the brain page.

Observational support is substantial:

• Hibbeln 2002 cross-national analysis: postpartum depression prevalence varies more than 50-fold across countries, inversely correlated with national per-capita fish consumption
• Multiple cohort studies: women with lower omega-3 index during pregnancy have higher postpartum depression incidence
• Breast milk docosahexaenoic acid concentration inversely correlates with postpartum depression scores

Randomized trial evidence is more modest. A 2018 review by Hsu et al. (J Affect Disord) concluded that eicosapentaenoic acid-rich oil reduced depression in pregnancy and after birth, while docosahexaenoic acid-rich oil begun in pregnancy and continued after childbirth had no beneficial effect on depression. The DOMInO trial specifically did not find a postpartum-depression benefit, in a relatively well-nourished Australian population.

In summary, the case for omega-3 in pregnancy and breastfeeding as a contributor to postpartum mood is strongest for women with a past history of depression, low fish intake, or other postpartum-depression risk factors, and the trial results are mixed. Omega-3 is not a treatment for established postpartum depression; the established treatments are selective serotonin reuptake inhibitors (SSRIs) and psychotherapy.

Back to Table of Contents

Mercury, PCBs, and Fish Consumption Guidance

The pregnancy fish-consumption question is complicated by methylmercury and PCB (polychlorinated biphenyl) contamination of seafood, particularly large predatory fish that biomagnify these toxins from the food chain. Methylmercury is a developmental neurotoxin; the Faroe Islands and Seychelles studies demonstrated that prenatal methylmercury exposure correlates with cognitive deficits in offspring.

The U.S. Food and Drug Administration and Environmental Protection Agency joint advice (first issued in 2017, revised October 2021) groups fish by mercury level; for pregnancy and breastfeeding, one serving is 4 oz:

• Best Choices (2-3 servings a week) — includes anchovy, Atlantic mackerel, catfish, clam, cod, crab, flounder, haddock, herring, oyster, pollock, salmon, sardine, scallop, shad, shrimp, squid, tilapia, freshwater trout, canned light tuna (including skipjack) and whiting
• Good Choices (1 serving a week) — includes bluefish, grouper, halibut, mahi mahi, monkfish, snapper, Spanish mackerel, striped bass, tilefish from the Atlantic, albacore (white) tuna canned or fresh/frozen, and yellowfin tuna
• Choices to Avoid (highest mercury levels) — king mackerel, marlin, orange roughy, shark, swordfish, tilefish from the Gulf of Mexico, bigeye tuna

For pregnant and breastfeeding women, the FDA/EPA advice states:

• 2 to 3 servings a week from the "Best Choices" list, or 1 serving from the "Good Choices" list; the Dietary Guidelines for Americans, which the advice supports, put intake at 8-12 oz a week of a variety of lower-mercury seafood
• The highest-mercury fish are grouped as "Choices to Avoid"
• Albacore (white) tuna is a "Good Choice" (1 serving a week); canned light tuna is a "Best Choice"

Docosahexaenoic acid supplements (algal sources in particular) supply docosahexaenoic acid without mercury.

The decision about whether to rely primarily on fish, primarily on supplements, or a combination depends on personal preference, baseline fish intake, and convenience. Women who already enjoy and consume 2-3 servings/week of low-mercury fatty fish typically achieve adequate omega-3 status without supplementation. For women who do not eat fish, the amount commonly cited is at least 200-300 mg/day of algal docosahexaenoic acid throughout pregnancy and breastfeeding.

Back to Table of Contents

Algal Docosahexaenoic Acid — the Clean Alternative

Algal docosahexaenoic acid is produced by fermentation of marine microalgae (primarily Crypthecodinium cohnii and Schizochytrium species). It is:

• Free of methylmercury, PCBs, dioxins, and persistent organic pollutants by virtue of fermentation production rather than wild harvest
• Vegetarian/vegan-suitable
• The original source of marine omega-3 in the food chain (fish acquire docosahexaenoic acid by consuming microalgae, directly or indirectly)
• U.S. Food and Drug Administration generally recognized as safe (GRAS) for use in infant formula and dietary supplements
• The docosahexaenoic acid source used in standard infant formulas globally

The primary practical difference from fish oil is that most algal preparations provide only docosahexaenoic acid (no significant eicosapentaenoic acid). This is well-suited for pregnancy/lactation indications where docosahexaenoic acid is the primary developmental need, but is not ideal for indications where eicosapentaenoic acid matters more (depression, inflammation, cardiovascular). In pregnancy, algal docosahexaenoic acid is typically taken at 200-500 mg/day.

Cost is somewhat higher per milligram of docosahexaenoic acid than fish oil, but the practical convenience (clean, plant-based, smaller dose, no fish taste) is why many pregnant women choose it, particularly those who do not consume fish.

Back to Table of Contents

Dosing for Pregnancy, Lactation, and Early Childhood

The amounts below are those used in trials and published recommendations; they are reported here, not prescribed.

• Preconception — the 2024 guideline (Cetin et al.) states at least 250 mg/day combined eicosapentaenoic acid+docosahexaenoic acid from food or supplements for women of childbearing age; 250-500 mg/day is the range commonly cited for building maternal stores before pregnancy, and some advice describes starting at least 3 months before planned conception
• Pregnancy (general) — a minimum of 200 mg/day docosahexaenoic acid per International Society for the Study of Fatty Acids and Lipids (ISSFAL) and European Food Safety Authority (EFSA) expert consensus; the 2024 guideline states an additional 100-200 mg/day or more of docosahexaenoic acid in pregnancy on top of the 250 mg/day baseline. Many published recommendations fall at 300-500 mg/day docosahexaenoic acid, taken from the first trimester through the end of pregnancy
• Pregnancy with low intake or low blood levels — the 2024 guideline states that pregnant women with low docosahexaenoic acid intake and/or low blood levels have a higher risk of preterm and early preterm birth and sets about 600-1,000 mg/day of docosahexaenoic acid+eicosapentaenoic acid (or docosahexaenoic acid alone) for them, preferably beginning in the second trimester (no later than about 20 weeks) and continuing to about 37 weeks or until birth if earlier. It notes that women with low intake can be identified with a short set of standard questions about what they eat, and that blood docosahexaenoic acid testing is another option still awaiting standard methods and cut-offs. These are also the doses used in the KUDOS and ADORE trials. The ORIP analysis above found extra omega-3 may raise early preterm birth in women whose levels are already high
• Lactation — 200-500 mg/day docosahexaenoic acid throughout breastfeeding is the range commonly cited. Maternal milk docosahexaenoic acid concentration directly reflects maternal intake; the mother's intake is the primary determinant of how much docosahexaenoic acid the breastfed infant receives
• Formula-fed infants — standard infant formulas already contain docosahexaenoic acid (and ARA, arachidonic acid)
• Breastfed infants of mothers with adequate docosahexaenoic acid intake — the mother's intake reaches the infant via milk
• Toddlers and young children (age 1-5) — for children not eating fish twice a week, 100-300 mg/day of docosahexaenoic acid (algal or fish-oil based) is the amount commonly cited. Continued docosahexaenoic acid intake supports ongoing brain development
• School-age children (age 6-12) — the FDA/EPA advice lists 2 servings a week from the “Best Choices” list for children; 200-400 mg/day combined eicosapentaenoic acid+docosahexaenoic acid is the amount commonly cited for children with low fish intake

Back to Table of Contents

Cautions in Pregnancy

• Vitamin A in cod liver oil — cod liver oil contains substantial vitamin A in addition to omega-3. Preformed retinol above 3,000 mcg RAE (retinol activity equivalents) a day in pregnancy is teratogenic (can harm the developing baby). Standard fish oil (no cod liver) does not contain significant vitamin A. Cod liver oil labels differ in whether they state the vitamin A content, and the total vitamin A dose depends on that figure. Algal docosahexaenoic acid contains no vitamin A
• Methylmercury and high-mercury fish — the FDA/EPA advice groups swordfish, king mackerel, Gulf of Mexico tilefish, shark, marlin, orange roughy and bigeye tuna as “Choices to Avoid” (highest mercury levels). Canned albacore tuna is a “Good Choice” (1 serving a week)
• Raw/undercooked fish (sushi, ceviche) — pregnancy food-safety guidance advises against raw fish because of Listeria, parasites, and other foodborne illness risks. Smoked fish (lox) is described as acceptable if pasteurized, which the label states
• Bleeding risk near delivery — mild antiplatelet effect of omega-3. Some obstetric protocols stop omega-3 supplementation 1-2 weeks before scheduled delivery; others continue through delivery without difficulty. The effect on bleeding is mild, and the question arises mainly with high doses
• Quality and contamination concerns — independent third-party testing programs exist that check fish-oil products for heavy metals, PCBs, and dioxins. Contamination matters more in pregnancy than in other uses
• Krill oil concerns — krill oil has not been specifically studied in pregnancy at scale. Algal docosahexaenoic acid and well-purified fish oil have more pregnancy data. Data on krill oil are thinner
• Storage and rancidity — rancid omega-3 may be pro-inflammatory rather than anti-inflammatory. Heat, air and time make fish oil go rancid; refrigeration after opening slows this, and a rancid (fishy, sour) smell is the usual sign that it has happened

Back to Table of Contents

Key Research Papers

1. Makrides M et al. (2010). Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children (DOMInO). JAMA — PubMed PMID: 20959577
2. Carlson SE et al. (2013). DHA supplementation and pregnancy outcomes (KUDOS). Am J Clin Nutr — PubMed PMID: 23426033
3. Middleton P et al. (2018). Omega-3 fatty acid addition during pregnancy. Cochrane Database — PubMed PMID: 30480773
4. Birch EE et al. (1998). Visual acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants. Pediatr Res — PubMed PMID: 9702915
5. Hibbeln JR et al. (2007). Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC). The Lancet — PubMed PMID: 17307104
6. Helland IB et al. (2003). Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. Pediatrics — PubMed PMID: 12509593
7. Hsu MC, Tung CY, Chen HE (2018). Omega-3 polyunsaturated fatty acid supplementation in prevention and treatment of maternal depression: Putative mechanism and recommendation. J Affect Disord 238:47-61 — PubMed PMID: 29860183
8. Carlson SE et al. (2021). Higher dose docosahexaenoic acid supplementation during pregnancy and early preterm birth: A randomised, double-blind, adaptive-design superiority trial (ADORE). EClinicalMedicine 36:100905 — PubMed PMID: 34308309
9. Makrides M et al. (2019). A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery (ORIP). NEJM — PubMed PMID: 31509674
10. Oken E et al. (2005). Maternal fish consumption, hair mercury, and infant cognition in a U.S. Cohort. Environ Health Perspect 113(10):1376-80 — PubMed PMID: 16203250
11. Sanders TA (2009). DHA status of vegetarians. Prostaglandins Leukot Essent Fatty Acids 81(2-3):137-41 — PubMed PMID: 19500961
12. Hibbeln JR (2002). Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J Affect Disord 69(1-3):15-29 — PubMed PMID: 12103448
13. Makrides M, Gould JF, Gawlik NR, Yelland LN, Smithers LG, Anderson PJ, Gibson RA (2014). Four-year follow-up of children born to women in a randomized trial of prenatal DHA supplementation. JAMA 311(17):1802-4 — PubMed PMID: 24794375
14. Gould JF, Treyvaud K, Yelland LN, Anderson PJ, Smithers LG, McPhee AJ, Makrides M (2017). Seven-Year Follow-up of Children Born to Women in a Randomized Trial of Prenatal DHA Supplementation. JAMA 317(11):1173-1175 — PubMed PMID: 28324081
15. Simmonds LA, Sullivan TR, Skubisz M, Middleton PF, Best KP, Yelland LN, Quinlivan J, Zhou SJ, Liu G, McPhee AJ, Gibson RA, Makrides M (2020). Omega-3 fatty acid supplementation in pregnancy-baseline omega-3 status and early preterm birth: exploratory analysis of a randomised controlled trial. BJOG 127(8):975-981 — PubMed PMID: 32034969
16. Cetin I, Carlson SE, Burden C, et al. (2024). Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth. Am J Obstet Gynecol MFM 6(2):101251 — PubMed PMID: 38070679

PubMed Topic Searches

1. PubMed: DHA pregnancy preterm birth
2. PubMed: Omega-3 infant brain visual
3. PubMed: Algal DHA vegetarian pregnancy
4. PubMed: Postpartum depression omega-3
5. PubMed: Methylmercury pregnancy

Back to Table of Contents

Connections

• All Food
• Omega-3 Fatty Acids Overview
• Omega-3 Benefits Hub
• Omega-3 for Cardiovascular Health
• Omega-3 for Brain & Cognition
• Omega-3 for Inflammation Resolution
• Vitamin D3
• Folate
• Vitamin A (and the cod liver oil caution)
• Iron
• Iodine (also critical in pregnancy)
• Mercury (toxicology)
• Salmon
• Sardines
• Depression (postpartum)
• History

Back to Table of Contents

Featured Videos